Comment Period - Intent to List Abiraterone Acetate
OEHHA is requesting comments as to whether Abiraterone acetate meets the criteria set forth in the Proposition 65 regulations for listings via the formally required to be labeled or identified mechanism (Section 25902). Because this is a ministerial listing, comments should be limited to whether FDA requires that abiraterone acetate be labeled to communicate a risk of reproductive or developmental harm. OEHHA cannot consider scientific arguments concerning the weight or quality of the evidence considered by FDA when it established the labeling requirement and will not respond to such comments if they are submitted.
In order to be considered, OEHHA must receive comments by 5:00 p.m. on Monday, February 29, 2016. We encourage you to submit comments in electronic form, rather than in paper form. Comments transmitted by e-mail should be addressed to P65Public.Comments@oehha.ca.gov. Please include “abiraterone acetate” in the subject line. Comments submitted in paper form may be mailed, faxed, or delivered in person to the address below.
Mailing Address: Michelle Robinson
Proposition 65 Implementation Program
Office of Environmental Health Hazard Assessment
P.O. Box 4010, MS-12B
Sacramento, California 95812-4010
Fax: (916) 323-2265
Street Address: 1001 I Street
Sacramento, California 95814
Comments received during the public comment period will be posted on the OEHHA web site after the close of the comment period.
If you have any questions, please contact Michelle Robinson at Michelle.Robinson@oehha.ca.gov or at (916) 445-6900.